Global sales of non-Chinese COVID vaccines will almost double in 2022

Posted on Aug 4, 2021

Airfinity expects the sale of non-Chinese vaccines to almost double next year from nearly $70 billion to almost $127 billion as more countries choose to buy the highly efficacious mRNA vaccines.

Western vaccines will be preferred over Chinese, so once they can be produced, they can be sold and will outcompete the less-effective Chinese vaccines. Many countries currently using Chinese candidates are turning to Western vaccines as 3rd shots to bolster immunity.

While China is currently the largest vaccine producer, most of its vaccines are being used domestically, with only 18% of their current production being exported. China has sold 1 billion vaccine doses to other countries in a global sales market of 14.1 billion. There are yet no sales of Chinese vaccines confirmed for 2022.

For more information or if you have specific data requests, contact the team.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022